IP Library › Granted Patent US 12,318,327
Granted Patent B2
US 12,318,327 · App. 18/300,790 · Granted Jun 3, 2025

Systems and methods for treating eye diseases

Inventors: Michael Calhoun (Lighthouse Point, FL); Jeff Franco (Plano, TX); Robert M. Vidlund (Forest Lake, MN)
Assignee: J.D. FRANCO & CO., LLC
A61F9/007A61B3/16A61B5/026A61B5/6866A61B17/12109A61B17/12136A61B17/221A61B17/320725A61B17/320758A61F2/856A61F9/00781A61M1/3621A61M1/3627A61M25/01A61M25/1002A61M25/104A61M27/00A61B2017/00986A61B17/12009A61B2017/22061A61B2017/22079A61B2090/064A61F2/82A61F2002/821A61M25/0068A61M2025/0186A61M2025/0681A61M2025/09008A61M2025/1052A61M2210/0612
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,318,327
App. No.
18/300,790
Granted
Jun 3, 2025
Kind
B2
Abstract

A method may include accessing a terminal branch of an ophthalmic artery through a face of a subject. Additionally, the method may include positioning a device within the ophthalmic artery of the subject and treating at least one of a blockage, a stenosis, a lesion, plaque or other physiology in at least one of the ophthalmic artery or a junction between an internal carotid artery and the ophthalmic artery.

Claims (26)

1. A method, comprising:

intravascularly accessing an ophthalmic artery (OA) of a subject;

positioning a device within the OA of the subject; and

treating a blockage, the blockage comprising a stenosis, a lesion, or plaque physiology in at least one location within one or both of the OA or a junction between an internal carotid artery (ICA) and the OA, wherein treating comprises removal or opening of the blockage, and wherein, as a result of the treating, an increased amount of blood reaches a retina of the subject, thereby affecting complement system (CS) activity within the retina.

2. The method of claim 1 , wherein the treating includes restoring or improving blood flow in the OA thereby improving a rate of delivery of nutrients, including oxygen, hemoglobin, or glucose to retinal tissue so as to affect CS activity.

3. The method of claim 1 , wherein the treating includes restoring or improving blood flow in the OA thereby improving removal of metabolic waste removal from cells, organs, or other biological structures.

4. The method of claim 1 , wherein the treating includes restoring or improving blood flow in the OA to treat photoreceptor dysfunction or degeneration.

5. The method of claim 1 , wherein the treating includes restoring or improving blood flow in the OA to treat retinal disease by eliminating, reducing, or mediating CS activation, regulated by retinal pigment epithelium (RPE).

6. The method of claim 1 , wherein the treating includes restoring or improving blood flow in the OA to treat retinal disease by eliminating, reducing, or mediating CS activation, regulated by choroid.

7. A method, comprising:

positioning a device within an ophthalmic artery (OA) of a subject; and

treating a blockage in at least one location within at least one of the OA or a junction between an internal carotid artery (ICA) and the OA, the treating comprising removal or opening of the blockage so as to restore or increase an amount of blood delivered to a retina of the subject to impact complement system (CS) activity within the retina.

8. The method of claim 7 , wherein the treating includes improving a rate of delivery of nutrients including oxygen, hemoglobin, or glucose to retinal tissue, to affect CS activity.

9. The method of claim 7 , wherein the treating includes improving removal of metabolic waste removal from cells, organs, or other biological structures.

10. The method of claim 7 , wherein the treating includes restoring or improving blood flow in the OA by treating photoreceptor dysfunction or degeneration.

11. The method of claim 7 , wherein the treating includes restoring or improving blood flow in the OA by treating retinal disease by eliminating, reducing, or mediating CS activation, regulated by retinal pigment epithelium (RPE).

12. The method of claim 7 , wherein the treating includes restoring or improving blood flow in the OA to treat retinal disease by eliminating, reducing, or mediating CS activation, regulated by choroid.

13. A method, comprising:

treating a blockage within at least one of an ophthalmic artery (OA) of a subject or a junction between an internal carotid artery (ICA) and the OA;

wherein treating the blockage comprises removal or opening of the blockage and angioplasty so as to restore or increase an amount of blood delivered to an eye of the subject to impact complement system (CS) activity within the eye.

14. The method of claim 13 , wherein the treating includes restoring or increasing an amount of blood delivered to a retina of the eye of the subject.

15. The method of claim 13 , wherein the treating includes improving a rate of delivery of nutrients including oxygen, hemoglobin, or glucose to retinal tissue, to affect CS activity.

16. The method of claim 13 , wherein the treating includes improving removal of metabolic waste removal from cells, organs, or other biological structures.

17. The method of claim 13 , wherein the treating includes restoring or improving blood flow in the OA by treating photoreceptor dysfunction or degeneration.

18. The method of claim 13 , wherein the treating includes restoring or improving blood flow in the OA by treating retinal disease by eliminating, reducing, or mediating CS activation, regulated by retinal pigment epithelium (RPE).

19. The method of claim 13 , wherein the treating includes restoring or improving blood flow in the OA to treat retinal disease by eliminating, reducing, or mediating CS activation, regulated by choroid.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 14, 2024
From: OCUDYNE, INC.
To: J.D. FRANCO & CO., LLC
Reel/Frame 069255/0866 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2024
From: CALHOUN, MICHAEL; FRANCO, JEFF; VIDLUND, ROBERT M.
To: OCUDYNE, INC.
Reel/Frame 069225/0894 →
Continuity (17)
Continuation 16932401 · Jul 17, 2020
Continuation 16789658 · Feb 13, 2020
Continuation 16583508 · Sep 26, 2019
Continuation 16415506 · May 17, 2019
Continuation 16228316 · Dec 20, 2018
Continuation In Part 15971809 · May 4, 2018
Continuation In Part PCTUS2017051551 · Sep 14, 2017
Continuation 15681075 · Aug 18, 2017
Continuation In Part 15609547 · May 31, 2017
Continuation PCTUS2017021673 · Mar 9, 2017
Continuation 14385496
Provisional Application 62396091 · Sep 16, 2016
Provisional Application 62395294 · Sep 15, 2016
Provisional Application 62314340 · Mar 28, 2016
Provisional Application 62305991 · Mar 9, 2016
Provisional Application 61679351 · Aug 3, 2012
Related Publication 20240082055A1 · Mar 14, 2024
References Cited (220)
US 2690595A · Raiche · 1954 [cited by applicant]
US 3367101A · Garnet et al. · 1968 [cited by applicant]
US 3435826A · Fogarty · 1969 [cited by applicant]
US 3970090A · Loiacono · 1976 [cited by applicant]
US 4224929A · Furihata · 1980 [cited by applicant]
US 4403612A · Fogarty · 1983 [cited by applicant]
US 4445897A · Ekbladh et al. · 1984 [cited by applicant]
US 4610662A · Weikl et al. · 1986 [cited by applicant]
US 4636195A · Wolinsky · 1987 [cited by applicant]
US 4794931A · Yock · 1989 [cited by applicant]
US 4857045A · Rydell · 1989 [cited by applicant]
US 4886061A · Fischell et al. · 1989 [cited by applicant]
US 4894051A · Shiber · 1990 [cited by applicant]
US 4898575A · Fischell et al. · 1990 [cited by applicant]
US 4926858A · Gifford, III et al. · 1990 [cited by applicant]
US 4936835A · Haaga · 1990 [cited by applicant]
US 4950277A · Farr · 1990 [cited by applicant]
US 4957482A · Shiber · 1990 [cited by applicant]
US 4979939A · Shiber · 1990 [cited by applicant]
US 4986807A · Farr · 1991 [cited by applicant]
US 5000185A · Yock · 1991 [cited by applicant]
US 5000734A · Boussignac et al. · 1991 [cited by applicant]
US 5007896A · Shiber · 1991 [cited by applicant]
US 5019088A · Farr · 1991 [cited by applicant]
US 5024651A · Shiber · 1991 [cited by applicant]
US 5026384A · Farr et al. · 1991 [cited by applicant]
US 5087265A · Summers · 1992 [cited by applicant]
US 5100425A · Fischell et al. · 1992 [cited by applicant]
US 5135531A · Shiber · 1992 [cited by applicant]
US 5176693A · Pannek, Jr. · 1993 [cited by applicant]
US 5292332A · Lee · 1994 [cited by applicant]
US 5313949A · Yock · 1994 [cited by applicant]
US 5314438A · Shturman · 1994 [cited by applicant]
US 5318576A · Plassche, Jr. et al. · 1994 [cited by applicant]
US 5336234A · Vigil et al. · 1994 [cited by applicant]
US 5366464A · Belknap · 1994 [cited by applicant]
US 5395311A · Andrews · 1995 [cited by applicant]
US 5402790A · Jang et al. · 1995 [cited by applicant]
US 5409454A · Fischell et al. · 1995 [cited by applicant]
US 5415634A · Glynn et al. · 1995 [cited by applicant]
US 5419761A · Narayanan et al. · 1995 [cited by applicant]
US 5507292A · Jang et al. · 1996 [cited by applicant]
US 5554119A · Harrison et al. · 1996 [cited by applicant]
US 5599307A · Bacher et al. · 1997 [cited by applicant]
US 5709701A · Parodi · 1998 [cited by applicant]
US 5820595A · Parodi · 1998 [cited by applicant]
US 5897567A · Ressemann et al. · 1999 [cited by applicant]
US 5951514A · Sahota · 1999 [cited by applicant]
US 5972019A · Engelson et al. · 1999 [cited by applicant]
US 6010522A · Barbut et al. · 2000 [cited by applicant]
US 6146370A · Barbut · 2000 [cited by applicant]
US 6206868B1 · Parodi · 2001 [cited by applicant]
US 6302908B1 · Parodi · 2001 [cited by applicant]
US 6336933B1 · Parodi · 2002 [cited by applicant]
US 6344054B1 · Parodi · 2002 [cited by applicant]
US 6413235B1 · Parodi · 2002 [cited by applicant]
US 6423032B2 · Parodi · 2002 [cited by applicant]
US 6451799B1 · Ogawa · 2002 [cited by examiner]
US 6494890B1 · Shturman et al. · 2002 [cited by applicant]
US 6540712B1 · Parodi et al. · 2003 [cited by applicant]
US 6595980B1 · Barbut · 2003 [cited by applicant]
US 6623471B1 · Barbut · 2003 [cited by applicant]
US 6626861B1 · Hart et al. · 2003 [cited by applicant]
US 6641573B1 · Parodi · 2003 [cited by applicant]
US 6645222B1 · Parodi et al. · 2003 [cited by applicant]
US 6824558B2 · Parodi · 2004 [cited by applicant]
US 6827726B2 · Parodi · 2004 [cited by applicant]
US 6837881B1 · Barbut · 2005 [cited by applicant]
US 6855162B2 · Parodi · 2005 [cited by applicant]
US 6902540B2 · Dorros et al. · 2005 [cited by applicant]
US 6905490B2 · Parodi · 2005 [cited by applicant]
US 6908474B2 · Hogendijk et al. · 2005 [cited by applicant]
US 6929634B2 · Dorros et al. · 2005 [cited by applicant]
US 6936053B1 · Weiss · 2005 [cited by applicant]
US 6936060B2 · Hogendijk et al. · 2005 [cited by applicant]
US 6974469B2 · Broome et al. · 2005 [cited by applicant]
US 7195611B1 · Simpson et al. · 2007 [cited by applicant]
US 7214201B2 · Burmeister et al. · 2007 [cited by applicant]
US 7235095B2 · Haverkost et al. · 2007 [cited by applicant]
US 7309334B2 · Von Hoffmann · 2007 [cited by applicant]
US 7384411B1 · Condado · 2008 [cited by applicant]
US 7604612B2 · Ressemann et al. · 2009 [cited by applicant]
US 7806906B2 · Don Michael · 2010 [cited by applicant]
US 7867273B2 · Pappas et al. · 2011 [cited by applicant]
US 7901445B2 · Wallace et al. · 2011 [cited by applicant]
US 7927347B2 · Hogendijk et al. · 2011 [cited by applicant]
US 8123779B2 · Demond et al. · 2012 [cited by applicant]
US 8157760B2 · Criado et al. · 2012 [cited by applicant]
US 8267956B2 · Salahieh et al. · 2012 [cited by applicant]
US 8353850B2 · Ressemann et al. · 2013 [cited by applicant]
US 8409237B2 · Galdonik et al. · 2013 [cited by applicant]
US 8414516B2 · Chang · 2013 [cited by applicant]
US 8439937B2 · Montague et al. · 2013 [cited by applicant]
US 8545432B2 · Renati et al. · 2013 [cited by applicant]
US 8834404B2 · Beaudin · 2014 [cited by applicant]
US 8852226B2 · Gilson et al. · 2014 [cited by applicant]
US 8863631B1 · Janardhan et al. · 2014 [cited by applicant]
US 9078682B2 · Lenker et al. · 2015 [cited by applicant]
US 9241699B1 · Kume et al. · 2016 [cited by applicant]
US 9259215B2 · Chou et al. · 2016 [cited by applicant]
US 9265512B2 · Garrison et al. · 2016 [cited by applicant]
US 9987164B2 · Calhoun · 2018 [cited by applicant]
US 10195077B2 · Calhoun et al. · 2019 [cited by applicant]
US 10265085B2 · Zaidat · 2019 [cited by applicant]
US 10342699B2 · Calhoun et al. · 2019 [cited by applicant]
US 10682253B2 · Calhoun et al. · 2020 [cited by applicant]
US 10751215B2 · Calhoun et al. · 2020 [cited by applicant]
US 20010001114A1 · Tsugita et al. · 2001 [cited by applicant]
US 20020038103A1 · Estrada et al. · 2002 [cited by applicant]
US 20020077656A1 · Ginn et al. · 2002 [cited by applicant]
US 20020087128A1 · Paques et al. · 2002 [cited by applicant]
US 20020143291A1 · Slater · 2002 [cited by applicant]
US 20020151922A1 · Hogendijk et al. · 2002 [cited by applicant]
US 20020165573A1 · Barbut · 2002 [cited by applicant]
US 20030023200A1 · Barbut et al. · 2003 [cited by applicant]
US 20030023227A1 · Zadno-Azizi et al. · 2003 [cited by applicant]
US 20030199802A1 · Barbut · 2003 [cited by applicant]
US 20030199819A1 · Beck · 2003 [cited by applicant]
US 20030203958A1 · Kunz et al. · 2003 [cited by applicant]
US 20050149117A1 · Khosravi et al. · 2005 [cited by applicant]
US 20060089618A1 · McFerran et al. · 2006 [cited by applicant]
US 20060136022A1 · Wong, Jr. et al. · 2006 [cited by applicant]
US 20060259132A1 · Schaffer et al. · 2006 [cited by applicant]
US 20070026035A1 · Burke et al. · 2007 [cited by applicant]
US 20080027304A1 · Pardo et al. · 2008 [cited by applicant]
US 20080027519A1 · Guerrero · 2008 [cited by applicant]
US 20080215117A1 · Gross · 2008 [cited by examiner]
US 20080243229A1 · Wallace et al. · 2008 [cited by applicant]
US 20090018455A1 · Chang · 2009 [cited by applicant]
US 20090024072A1 · Criado et al. · 2009 [cited by applicant]
US 20090030323A1 · Fawzi et al. · 2009 [cited by applicant]
US 20090221961A1 · Tal et al. · 2009 [cited by applicant]
US 20090319017A1 · Berez · 2009 [cited by examiner]
US 20100076365A1 · Riina et al. · 2010 [cited by applicant]
US 20100100045A1 · Pravongviengkham et al. · 2010 [cited by applicant]
US 20100125244A1 · McAndrew · 2010 [cited by applicant]
US 20100234884A1 · Lafontaine et al. · 2010 [cited by applicant]
US 20110143993A1 · Langer et al. · 2011 [cited by applicant]
US 20110152683A1 · Gerrans et al. · 2011 [cited by applicant]
US 20110152998A1 · Berez et al. · 2011 [cited by applicant]
US 20110160762A1 · Hogendijk et al. · 2011 [cited by applicant]
US 20110274748A1 · Robinson et al. · 2011 [cited by applicant]
US 20120046679A1 · Patel et al. · 2012 [cited by applicant]
US 20120078287A1 · Barbut · 2012 [cited by applicant]
US 20120101510A1 · Lenker et al. · 2012 [cited by applicant]
US 20130035628A1 · Garrison et al. · 2013 [cited by applicant]
US 20130197621A1 · Ryan et al. · 2013 [cited by applicant]
US 20130281788A1 · Garrison · 2013 [cited by applicant]
US 20140154246A1 · Robinson et al. · 2014 [cited by applicant]
US 20140222066A1 · Tegels · 2014 [cited by applicant]
US 20150025562A1 · Dinh et al. · 2015 [cited by applicant]
US 20150032121A1 · Janardhan et al. · 2015 [cited by applicant]
US 20150065804A1 · Kleyman · 2015 [cited by applicant]
US 20150231378A1 · Pepper · 2015 [cited by applicant]
US 20150272732A1 · Tilson et al. · 2015 [cited by applicant]
US 20150313607A1 · Zhadkevich · 2015 [cited by applicant]
US 20150359547A1 · Vale et al. · 2015 [cited by applicant]
US 20150359549A1 · Lenker et al. · 2015 [cited by applicant]
US 20150366580A1 · Lenihan et al. · 2015 [cited by applicant]
US 20160166754A1 · Kassab et al. · 2016 [cited by applicant]
US 20160317328A1 · Berez et al. · 2016 [cited by applicant]
US 20170164963A1 · Goyal · 2017 [cited by applicant]
US 20170239453A1 · Kawakita et al. · 2017 [cited by applicant]
US 20170311963A1 · Farhat et al. · 2017 [cited by applicant]
US 20170326001A1 · Franco et al. · 2017 [cited by applicant]
US 20170348120A1 · Calhoun et al. · 2017 [cited by applicant]
US 20180132876A1 · Zaidat · 2018 [cited by applicant]
US 20200022837A1 · Calhoun et al. · 2020 [cited by applicant]
EP 2495006 · 2012 [cited by applicant]
WO WO9852639A1 · 1998 [cited by applicant]
WO WO9853761A1 · 1998 [cited by applicant]
WO WO0054673A1 · 2000 [cited by applicant]
WO WO03018085A2 · 2003 [cited by applicant]
WO WO2007103464A2 · 2007 [cited by applicant]
WO WO2012162651 · 2012 [cited by applicant]
WO WO2014022866A1 · 2014 [cited by applicant]
WO WO2016109586A1 · 2016 [cited by applicant]
WO WO2016149653 · 2016 [cited by applicant]
WO WO2017156333A1 · 2017 [cited by applicant]
WO WO2018053121A1 · 2018 [cited by applicant]
WO WO2018106858A1 · 2018 [cited by applicant]
Altinbas, N.K. et al., “Effect of Carotid Artery Stenting on Ophthalmic Artery Flow Patterns,” Journal of Ultrasound Medicine, 2014; 33: pp. 629-638. [cited by applicant]
Ambarki, K. et al., “Blood Flow of Ophthalmic Artery in Healthy Individuals Determined by Phase-Contrast Magnetic Resonance Imaging,” Investigative Ophthalmology & Visual Science, 2013; 54: pp. 2738-2745. [cited by applicant]
Hwang, G. et al., “Reversal of Ischemic Retinopathy Following Balloon Angioplasty of a Stenotic Ophthalmic Artery.” Journal of Neuro-Ophthalmology 30.3, 2010, pp. 228-230. [cited by applicant]
Kane, A.G. et al., “Reduced Caliber of the Internal Carotid Artery: A Normal Finding with Ipsilateral Absence or Hypoplasia of the A1 Segment,” American Journal of Neuroradiology, 1996; 17: pp. 1295-1301. [cited by applicant]
Kawa, M.P. et al., “Complement System in Pathogenesis of AMD: Dual Player in Degeneration and Protection of Retinal Tissue,” Hindawi Publishing Corporation, Journal of Immunology Research, vol. 2014, Article ID 483960, … [cited by applicant]
Klein, R. et al., “Vasodilators, Blood Pressure-Lowering Medications, and Age-Related Macular Degeneration,” American Academy of Ophthalmology, 2014, vol. 121, Issue 8, pp. 1604-1611. [cited by applicant]
Kooragayala, K. et al., “Quanitification of Oxygen Consumption in Retina Ex Vivo Demonstrates Limited Reserve Capacity of Photoreceptor Mitochondria,” Investigative Ophthalmology & Visual Science, 2015; 56: pp. 8428-843… [cited by applicant]
Krejza, J. et al., “Carotid Artery Diameter in Men and Women and the Relation to Body and Neck Size,” Stroke, 2006; 3 pages. [cited by applicant]
Lanzino, G. et al., “Treatment of Carotid Artery Stenosis: Medical Therapy, Surgery, or Stenting?,” Mayo Clinic Proceedings, Apr. 2009; 84(4), pp. 362-368. [cited by applicant]
Michalinos, A. et al., “Anatomy of the Ophthalmic Artery: A Review concerning Its Modern Surgical and Clinical Applications,” Hindawi Publishing Corporation, Anatomy Research International, vol. 2015, Article ID 591961,… [cited by applicant]
Paques, M. et al., “Superselective ophthalmic artery fibrinolytic therapy for the treatment of central retinal vein occlusion.” British Journal of Ophthalmology, 2000, 84: 1387-1391. [cited by applicant]
Tan, P.L. et al., “AMD and the alternative complement pathway: genetics and functional implications,” Human Genomics, 2016, 10:23, 13 pages. [cited by applicant]
Xu, H. et al., “Targeting the complement system for the management of retinal inflammatory and degenerative diseases,” European Journal of Pharmacology, 2016, 787, pp. 94-104. [cited by applicant]
Yamane, T. et al., “The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma,” International Journal of Clinical Oncology, Apr. 2004; vol. 9, Issue 2, pp. 69-73. [cited by applicant]
Zeumer, H. et al., “Local intra-arterial fibrinolytic therapy in patients with stroke: urokinase versus recombinant tissue plagminogen activator (r-TPA),” Neuroradiology, 1993; 35: pp. 159-162. [cited by applicant]
Zipfel, P.F., et al., “The Role of Complement in AMD,” Inflammation and Retinal Disease: Complement Biology and Pathology, Advances in Experimental Medicine and Biology, 2010, 703, pp. 9-24. [cited by applicant]
Examination Report No. 2 for AU Application No. 2013296195, dated Jun. 27, 2017 (6 pages). [cited by applicant]
Notice of Allowance for KR 20157005602, dated Sep. 25, 2017 (3 pages). [cited by applicant]
Loh, K. et al., “Prevention and management of vision loss relating to facial filler injections.” Singapore Medical Journal, 2016; 57(8): 438-443. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/0051551, dated Dec. 15, 2017 (14 pages). [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2017/0052901, dated Dec. 8, 2017 (9 pages). [cited by applicant]
Bird, B. et al., “Anatomy, Head and Neck, Ophthalmic Arteries,” NCBI Bookshelf, a service of the National Library of Medicine, National Institutes of Health, Oct. 27, 2018, 5 pages. www.ncbi.nlm.nih.gov/books/NBK482317/. [cited by applicant]
Hattenbach, L. et al., “Experimental Endoscopic Endovascular Cannulation: A Novel Approach to Thrombolysis in Retinal Vessel Occlusion,” Investigative Ophthalmology & Visual Science, Jan. 2012, vol. 53, No. 1, pp. 42-46. [cited by applicant]
Khan, T.T. et al., “An Anatomical Analysis of the Supratrochlear Artery: Considerations in Facial Filler Injections and Preventing Vision Loss,” Aesthetic Surgery Journal, 2017, vol. 37(2), pp. 203-208. [cited by applicant]
Schumacher, M. et al., “Intra-arterial fibrinolytic therapy in central retinal artery occlusion,” Neuroradiology (1993) 35: pp. 600-605. [cited by applicant]
Schwenn, O.K. et al., “Experimental Percutaneous Cannulation of the Supraorbital Arteries: Implication for Future Therapy,” Investigative Ophthalmology & Visual Science, May 2005, vol. 46, No. 5, pp. 1557-1560. [cited by applicant]
Wang, R. et al., “Evaluation of Ophthalmic Artery Branch Retrograde Intervention in the Treatment of Central Retinal Artery Occlusion (CRAO),” Medical Science Monitor, 2017, 23: pp. 114-120. [cited by applicant]
Zhao, W. et al. “Three-Dimensional Computed Tomographic Study on the Periorbital Branches of the Ophthalmic Artery: Arterial Variations and Clinical Relevance,” Aesthetic Surgery Journal, 2018, pp. 1-9. [cited by applicant]
International Search Report and Written Opinion for corresponding PCT/US2013/053670, dated Dec. 26, 2013 (16 pp.). [cited by applicant]
Hayreh et al. “Ocular Arterial Occlusive Disorders and Carotid Artery Disease,” American Academy of Ophthalmology, 2017; vol. 1, No. 1: pp. 12-18. [cited by applicant]
Hayreh et al. “The Ophthalmic Artery,” British Journal of Ophthalmology, 1962; 46, 65: pp. 65-98. [cited by applicant]
Hayreh, S.S., “The Ophthalmic Artery III. Branches,” British Journal of Ophthalmology, 1962, 46, pp. 212-247. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2018/031229, dated Jul. 27, 2018 (19 pages). [cited by applicant]
Mazur et al., Catheterization and Cardiovascular Diagnosis, vol. 31, Issue 1, Abstract (1994). [cited by applicant]
Aurboonyawat et al., “Indirect Carotid-Cavernous Sinus Fistulas Treated by Transvenous Approach Through the Superior Ophthalmic Vein: A Case Report and Technical Note,” Siriraj Med. J., vol. 59, pp. 191-194, 2007. [cited by applicant]
Kleintjes, “Forehead anatomy: Arterial variations and venous link of the midline forehead flap,” Journal of Plastic, Reconstructive & Aesthetic Surgery, vol. 60, Issue 6, pp. 593-606, 2007. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2018/014766, dated Mar. 29, 2018 (7 pages). [cited by applicant]
Galassi et al. “Ocular Hemodynamics and Glaucoma Prognosis: A Color Doppler Imaging Study.” Arch Ophthalmol; 2003; 121(12):1711-1715; doi:10.1001/archopht.121.12.1711. [cited by applicant]
International Search Report and Written Opinion for International Application No. PCT/US2019/068758, dated May 29, 2020 (16 pages). [cited by applicant]